Copyright
©The Author(s) 2021.
World J Gastroenterol. Feb 14, 2021; 27(6): 501-512
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.501
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.501
Table 3 Receiver operating characteristic curve comparison analyses of each serum tumor marker
ROC curve | ΔAUC1 | Standard error | Z statistic | P value |
CA19-9 vs CEA | 0.115 | 0.038 and 0.042 | 2.03 | 0.04 |
CA19-9 vs CA125 | 0.183 | 0.038 and 0.051 | 2.88 | 0.004 |
CA19-9 vs CA724 | 0.148 | 0.038 and 0.058 | 2.14 | 0.03 |
CA19-9 vs CA242 | 0.008 | 0.038 and 0.090 | 0.08 | 0.81 |
CEA vs CA125 | 0.068 | 0.042 and 0.051 | 1.03 | 0.30 |
CEA vs CA724 | 0.033 | 0.042 and 0.058 | 0.46 | 0.62 |
CA125 vs CA724 | 0.035 | 0.051 and 0.058 | 0.45 | 0.63 |
- Citation: Sun LQ, Peng LS, Guo JF, Jiang F, Cui F, Huang HJ, Jin ZD. Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas. World J Gastroenterol 2021; 27(6): 501-512
- URL: https://www.wjgnet.com/1007-9327/full/v27/i6/501.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i6.501